Grant of Covenant Waiver and Covenant Reset

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Grant of Covenant Waiver and Covenant Reset

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in-class, specialist neonatal intensive care medical devices, announces that the Company's lender, HSBC, has granted a waiver in respect of the EBITDA covenant for the 31 October 2024 test date and a reset of such covenant at a lower level for the 31 January 2025 test date. The interest cover and net leverage covenants have also been reset for the period through to 31 January 2026.  The requirement for the waiver and reset of the covenants is a result of the previously announced trading conditions noted in the Group's interim results.

In addition, the Company's lender will allow drawdowns on the Revolving Credit Facility ("RCF") up to £7.8 million, sufficient to cover the funds required to meet the deferred consideration payment for Airon Corporation (of up to $1.0 million) due in June 2025. The Company will also continue to be able to draw down on the £5.0 million Invoice Financing Facility to cover day to day working capital requirements, which taken together with the RCF, the Directors believe provides sufficient liquidity headroom for the Group going forward.

For further information, please contact:

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy.  In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, South London and from its facility in Hailsham, East Sussex, and in the USA from its facility in Melbourne, Florida.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com